Healthcare System Reform and Reimbursement Rate Reduction Risk
First written in FY2016. 20 of 22 entries say "Materialised", first in FY2017-Q1. Latest entry: FY2025.
Asahi Intecc moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「A bundled payment system for medical services was introduced at advanced treatment hospitals in April 2003, and reductions in insurance reimbursement prices have been implemented every other year since April 2002. If medical system reforms cause effects such as a decline in selling prices, the performance of the Group may also be affected.」
The risk of lower selling prices resulting from medical system reforms, the bundled payment system for medical services, and reductions in insurance reimbursement prices continues to be disclosed. - FY2023-Q3MaterialisedAnnual report
「In the domestic market, revenue from the gastrointestinal field increased, but overall revenue declined due to the decline in medical reimbursement prices and a decrease in OEM transactions, among other factors.」
The decline in medical reimbursement prices directly contributed to lower domestic-market revenue during the cumulative third quarter, despite an increase in gastrointestinal revenue. - FY2023-Q2MaterialisedAnnual report
「In the domestic market, revenue declined due to the decline in medical reimbursement prices and a decrease in OEM transactions, among other factors.」
The decline in medical reimbursement prices directly contributed to the decrease in domestic revenue during the cumulative second quarter. - FY2023-Q1MaterialisedAnnual report
「In the domestic market, revenue declined due to the decline in medical reimbursement prices and a decrease in OEM transactions, among other factors.」
The decline in medical reimbursement prices is described as a direct factor contributing to lower revenue in the domestic medical business during the first quarter. - FY2022MaterialisedAnnual report
「In the domestic market, cardiovascular products, including PCI guidewires and therapeutic catheters, as well as peripheral vascular and neurovascular products, continued to perform well. However, revenue remained flat due to the decline in medical reimbursement prices, returns of gastrointestinal products associated with the switch to direct sales, and a decrease in OEM transactions.」
The decline in medical reimbursement prices is described as a direct impact on the domestic medical business during the fiscal year. - FY2021MaterialisedAnnual report
「In the domestic market, while the effects of the continued decrease in case volumes compared with normal levels due to COVID-19 remained, sales of products in the peripheral vascular and neurovascular fields of non-cardiovascular applications increased. However, revenue declined due to the decline in medical reimbursement prices and other factors.」
It states that the decline in medical reimbursement prices, together with the decrease in case volumes caused by COVID-19, directly contributed to lower revenue in the domestic medical business. - FY2021-Q3MaterialisedAnnual report
「In the domestic market, sales of neurovascular guiding catheters in non-cardiovascular applications increased, but revenue declined due to the decrease in case volumes and other effects, including the decline in medical reimbursement prices, resulting from COVID-19.」
The decrease in case volumes caused by COVID-19 and the decline in medical reimbursement prices continued to directly contribute to lower revenue in the domestic medical business during the cumulative third quarter. - FY2021-Q2MaterialisedAnnual report
「In the domestic market, sales of neurovascular guiding catheters in non-cardiovascular applications increased, but revenue declined due to the decrease in case volumes caused by COVID-19, the decline in medical reimbursement prices, and temporary sales delays resulting from an IT disruption caused by unauthorized access.」
It states that the decrease in case volumes caused by COVID-19 and the decline in medical reimbursement prices directly affected domestic revenue during the cumulative second quarter. - FY2021-Q1MaterialisedAnnual report
「In the domestic market, sales of neurovascular guiding catheters in non-cardiovascular applications continued to perform well, but revenue declined due to the decrease in case volumes caused by COVID-19 and the decline in medical reimbursement prices.」
The decrease in case volumes caused by COVID-19 and the decline in medical reimbursement prices directly affected domestic revenue in the first quarter. - FY2020MaterialisedAnnual report
「In the domestic market, sales declined from April 2020 onward due to a decrease in the number of cases caused by COVID-19 and a decline in medical reimbursement prices following the consumption-tax increase.」
The company states that lower medical reimbursement prices, together with the decline in the number of cases, actually affected full-year results in the domestic market. - FY2020-Q3MaterialisedAnnual report
「In the domestic market, although medical reimbursement prices declined following the consumption-tax increase and the number of cases declined against the backdrop of stricter procedural requirements for stable angina, sales increased because products including neurovascular balloon guide catheters in the non-cardiovascular field performed steadily.」
The decline in medical reimbursement prices following the consumption-tax increase and the decline in the number of cases resulting from stricter procedural requirements continued to occur in the domestic market. - FY2020-Q2MaterialisedAnnual report
「In the domestic market, although medical reimbursement prices declined following the consumption-tax increase and the number of cases declined against the backdrop of stricter procedural requirements for stable angina, sales increased because cardiovascular penetration catheters performed well, neurovascular guidewires, neurovascular balloon guide catheters and peripheral vascular guidewires in the non-cardiovascular field performed steadily, and OEM transactions for cardiovascular diagnostic and gastrointestinal applications remained strong.」
The decline in medical reimbursement prices following the consumption-tax increase and the decline in the number of cases resulting from stricter procedural requirements actually occurred in the domestic market during the six-month period under review. - FY2020-Q1MaterialisedAnnual report
「In the domestic market, the number of cases declined year on year due to stricter procedural requirements for stable angina. However, sales increased because cardiovascular penetration catheters remained steady, while cardiovascular penetration catheters and neurovascular guidewires in the non-cardiovascular field performed steadily.」
The number of cases declined against the backdrop of stricter procedural requirements for stable angina, indicating that risks related to the healthcare system and procedural requirements actually emerged in the domestic market during the quarter. However, domestic sales increased due to higher product sales. - FY2019MaterialisedAnnual report
「In the domestic market, volumes of PTCA guidewires, PTCA balloon catheters and diagnostic guidewires in the cardiovascular field, as well as neurovascular product groups in the non-cardiovascular field, increased and market share improved. However, sales declined in both the cardiovascular and non-cardiovascular fields due to lower medical reimbursement prices and a decline in the number of cases resulting from stricter procedural requirements for stable angina.」
The company states that lower medical reimbursement prices and the decline in the number of cases resulting from stricter procedural requirements affected full-year domestic sales. - FY2019-Q3MaterialisedAnnual report
「In the domestic market, PTCA guidewires, penetration catheters, PTCA balloon catheters and diagnostic guidewires in the cardiovascular field, as well as neurovascular guidewires in the non-cardiovascular field, performed steadily, with market share gains. However, sales declined in both the cardiovascular and non-cardiovascular fields due to lower medical reimbursement prices and a decline in the number of cases resulting from stricter procedural requirements for stable angina.」
The company states that the decline in the number of cases resulting from lower medical reimbursement prices and stricter procedural requirements affected domestic sales during the nine-month period under review. - FY2019-Q2MaterialisedAnnual report
「In the domestic market, PTCA guidewires, PTCA balloon catheters and diagnostic guidewires in the cardiovascular field, as well as neurovascular guidewires in the non-cardiovascular field, performed steadily, with market share gains. However, sales declined in both the cardiovascular and non-cardiovascular fields due to the impact of lower medical reimbursement prices and a decline in the number of cases resulting from stricter procedural requirements for stable angina.」
The company states that, in addition to lower medical reimbursement prices, stricter procedural requirements for stable angina and the resulting decline in the number of cases actually affected domestic sales. - FY2019-Q1MaterialisedAnnual report
「Although the Medical Devices business was negatively affected in the domestic market by lower medical reimbursement prices, it performed steadily due to strong demand in overseas markets.」
The company states that lower medical reimbursement prices had an actual negative impact on the domestic Medical Devices business in the first quarter, reducing sales in both the domestic cardiovascular and non-cardiovascular fields. - FY2017MaterialisedAnnual report
「In the domestic market, although the company was affected by the reduction in medical reimbursement prices in April 2016, sales increased as penetration catheters in the cardiovascular field grew substantially, led by the new SASUKE product.」
The company states that the April 2016 reduction in medical reimbursement prices actually affected the domestic market, while domestic sales increased due to growth in the new product. - FY2017-Q3MaterialisedAnnual report
「Although external factors including exchange-rate trends and declines in medical reimbursement prices had an impact, demand remained firm, led by overseas sales in the Medical Devices business. Consolidated net sales for the nine-month period under review were ¥31,579 million, up 4.1% year on year.」
The company states that exchange-rate trends and lower medical reimbursement prices continued to affect results as external factors. - FY2017-Q2MaterialisedAnnual report
「In the domestic market, although the company was affected by the reduction in medical reimbursement prices in April 2016, sales increased as penetration catheters in the cardiovascular field grew substantially, led by the new SASUKE product.」
The company states that the April 2016 reduction in medical reimbursement prices actually affected domestic-market results. However, domestic sales increased due to growth in penetration catheters, led by SASUKE. - FY2017-Q1MaterialisedAnnual report
「Although demand remained firm, as before, consolidated net sales for the first quarter of the current fiscal year were ¥9,988 million, down 2.4% year on year, due to the impact of external factors including exchange-rate trends and declines in medical reimbursement prices.」
The company states that lower medical reimbursement prices actually affected net sales as an external factor, while domestic-market sales remained flat. - FY2016First statedAnnual report
「In Japan, healthcare-system reforms are being pursued to control national medical expenditure associated with the rapid aging of the population and to resolve the disparity between domestic and overseas prices. A prospective payment system for advanced treatment hospitals was introduced in April 2003, and reimbursement prices have been reduced every 2 years since April 2002.」
The company states that measures to control medical expenditure, the prospective payment system and reductions in reimbursement prices could cause selling prices to decline.